Clos­ing in on an­oth­er mega-raise, UK biotech star Im­muno­core grabs $40M in­vest­ment from Gates Foun­da­tion

As re­ports cir­cu­late that the British biotech star Im­muno­core is in the fi­nal leg of pulling to­geth­er an­oth­er mega-raise, the ex­ec­u­tive crew at the TCR com­pa­ny has lined it­self up for a $40 mil­lion in­vest­ment from the Gates Foun­da­tion to fu­el an ex­pan­sion in­to in­fec­tious dis­ease R&D while tack­ling an in­cred­i­bly elu­sive tar­get.

While Im­muno­core is known pri­mar­i­ly for its work us­ing sol­u­ble T cell re­cep­tors and com­bin­ing them with an­ti­body frag­ments to cre­ate new can­cer ther­a­pies, part of the sec­ond wave of new tech com­ing in be­hind CAR-T, the foun­da­tion is us­ing its cash to point Im­muno­core to one of the Holy Grails in HIV re­search — elim­i­nat­ing the reser­voir of virus that lies hid­den and dor­mant in­side pa­tients’ cells whose dis­ease is kept un­der wraps by the cock­tail ther­a­pies that make up a multi­bil­lion dol­lar mar­ket. Gates’ in­vest­ment is al­so fund­ing a pro­gram for tu­ber­cu­lo­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER